182 related articles for article (PubMed ID: 23519576)
1. Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.
Ring A; Rathgen K; Stangier J; Reilly P; Clemens A; Friedman J
Clin Drug Investig; 2013 May; 33(5):333-42. PubMed ID: 23519576
[TBL] [Abstract][Full Text] [Related]
2. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
[TBL] [Abstract][Full Text] [Related]
3. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
4. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
[TBL] [Abstract][Full Text] [Related]
5. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
[TBL] [Abstract][Full Text] [Related]
6. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
Kempsford R; Allen A; Kelly K; Saggu P; Crim C
Br J Clin Pharmacol; 2014 Mar; 77(3):466-79. PubMed ID: 24093504
[TBL] [Abstract][Full Text] [Related]
7. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
8. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
9. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Ring A; Brand T; Macha S; Breithaupt-Groegler K; Simons G; Walter B; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2013 Apr; 12():70. PubMed ID: 23617452
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.
Härtter S; Sennewald R; Schepers C; Baumann S; Fritsch H; Friedman J
Eur J Clin Pharmacol; 2013 Mar; 69(3):327-39. PubMed ID: 22782539
[TBL] [Abstract][Full Text] [Related]
11. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
[TBL] [Abstract][Full Text] [Related]
12. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
[TBL] [Abstract][Full Text] [Related]
13. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.
Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ
Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
15. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
[TBL] [Abstract][Full Text] [Related]
16. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
Ring A; Port A; Graefe-Mody EU; Revollo I; Iovino M; Dugi KA
Br J Clin Pharmacol; 2011 Jul; 72(1):39-50. PubMed ID: 21306414
[TBL] [Abstract][Full Text] [Related]
17. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
18. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
19. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Hoch M; Darpo B; Brossard P; Zhou M; Stoltz R; Dingemanse J
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):429-37. PubMed ID: 25287214
[TBL] [Abstract][Full Text] [Related]
20. Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers.
Kropeit D; Johnson M; Cawello W; Rudd GD; Horstmann R
Acta Neurol Scand; 2015 Nov; 132(5):346-54. PubMed ID: 25932544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]